AKBA logo

AKEBIA THERAPEUTICS INC

AKBANASDAQ
🏆 #3593 by market capEarnings Nov 9US Equity
$632.69▼ $5.38 (−0.85%)
Simulated price
🔔
Track AKBA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$238M
Small Cap
📈Revenue Growth (YoY)
+47.5%
High Growth
📊Gross Margin
79.5%
High
💵FCF Margin
18.4%
Healthy
⚖️P/S Ratio
1.1x
Cheap
Otter Score
64
Fair
No chart data available for AKBA.

Trading Snapshot

Day Range
$628.53 – $635.69
52-Week Range
$0.81 – $3.20
Volume
$4.69B
Avg Volume
$5.95B
Shares Outstanding
268.3M
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$236M
Last Q Revenue
$49M
P/E Ratio
-8.2
P/S Ratio
1.1x
EPS (TTM)
$-0.11
Dividend Yield
0.00%
Dilution (1yr)
+21.3%

Why Investors Own AKBA

  • ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 37% gross margin and 30% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AKBA logo

AKEBIA THERAPEUTICS INC

AKBA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$236M▲ +47.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
83.3%▲ +37.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$23M▼ −146.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$68M▼ −267.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
265.4M▲ +21.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$133M▲ +$270M YoY
StockOtter · stockotter.space

About AKEBIA THERAPEUTICS INC

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$641.58
▲ +1.4% Upside
High Target$734.71
Low Target$509.44
Based on 19 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

AKEBIA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift AKBA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

AKEBIA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.